Alpha-Dunnione

Alpha-Dunnione

SCHEMBL940069

CC1OC2=C(C(=O)c3ccccc3C2=O)C1(C)C

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 4/20 0.56
POR P16435 4/20 0.56
IDO1 P14902 10/20 0.49
AKT1 P31749 1/20 0.41
ELANE P08246 1/20 0.39
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
CDC25B P30305 1/20 0.37
KDM4E B2RXH2 3/20 0.37
MAPT P10636 3/20 0.37
THRB P10828 3/20 0.37
RECQL P46063 3/20 0.37
BLM P54132 3/20 0.37
ALDH1A1 P00352 2/20 0.37
TP53 P04637 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C9 P11712 2/20 0.37
ALOX15 P16050 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(3R)-Dunnione SCHEMBL29468606 0.88 NQO1 (0.63) NQO1PORIDO1AKT1ELANE
(3R)-Dunnione SCHEMBL103115 0.88 NQO1 (0.63) NQO1PORIDO1AKT1ELANE
(3R)-Dunnione SCHEMBL6052903 0.82 NQO1 (0.56) NQO1PORIDO1AKT1ELANE
SCHEMBL8260282 0.81 NQO1 (0.52) NQO1PORIDO1AKT1ELANE
SCHEMBL6052838 0.74 NQO1 (0.57) NQO1PORIDO1AKT1ELANE
(3R)-Dunnione SCHEMBL8535310 0.73 NQO1 (0.47) NQO1PORIDO1MEN1KMT2A
SCHEMBL3329489 0.72 NQO1 (0.50) NQO1PORIDO1ELANEMEN1
SCHEMBL3331249 0.72 NQO1 (0.50) NQO1PORIDO1ELANEMEN1
SCHEMBL6052899 0.69 NQO1 (0.67) NQO1PORIDO1ELANEKDM4E
SCHEMBL10353380 0.68 DNMT3B (0.40) NQO1PORKDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0888326-B1 NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH WISCONSIN ALUMNI RES FOUND (US) 2006-08-16 EP claimed
JP-2000506841-A 2000-06-06 JP claimed
EP-0888326-A2 NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1999-01-07 EP claimed
WO-1997031936-A2 NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1997-09-04 WO claimed
CN-121181506-A Alpha-Dunnione analogue, preparation method and application thereof 西华大学 2025-12-23 CN disclosed
CN-121181506-A Alpha-Dunnione analogue, preparation method and application thereof 西华大学 2025-12-23 CN disclosed
EP-3284464-B1 COMPOSITION FOR PREVENTING AND TREATING PANCREATITIS CONTAINING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT NADIANBIO LTD (KR) 2025-08-13 EP disclosed
US-12370170-B2 Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment NADIANBIO LTD. (KR) 2025-07-29 US disclosed
US-20250170252-A1 QUINONE PROTECTED FORMS AND CONJUGATES CAMBRIDGE ENTERPRISE LIMITED (GB) 2025-05-29 US disclosed
EP-3449920-B1 COMPOSITION COMPRISING DUNNIONE OR BETA-LAPACHONE AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT NADIANBIO LTD (KR) 2025-05-28 EP disclosed
EP-4532480-A1 QUINONE PROTECTED FORMS AND CONJUGATES Cambridge Enterprise Limited (GB) 2025-04-09 EP disclosed
US-12257230-B2 Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment NADIANBIO LTD. (KR) 2025-03-25 US disclosed
EP-0888326-B1 NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH WISCONSIN ALUMNI RES FOUND (US) 2006-08-16 EP disclosed
EP-1567515-A2 NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF ARQULE, INC. (US) 2005-08-31 EP disclosed
US-20040266857-A1 Novel lapachone compounds and methods of use thereof HINES GLOBAL EDUCATION 2004-12-30 US disclosed
WO-2004045557-A2 NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF ARQULE, INC. (US) 2004-06-03 WO disclosed
US-5969163-A CONTACTING SOLUTION OF LAWSONE IN DIMETHYL SULFOXIDE AT LOW TEMPERATURE WITH LITHIUM HYDRIDE AND WARMING TO FORM LITHIUM SALT, ALKYLATING WITH ALLYL HALIDE IN PRESENCE OF LITHIUM IODIDE, CYCLIZING ALKYLATED LAWSONE DERIVATIVES WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1999-10-19 US disclosed
EP-0888326-A2 NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1999-01-07 EP disclosed
US-5824700-A ANTICARCINOGENIC AGENTS FOR TREATING BREAST CANCER OR COLON CANCER WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1998-10-20 US disclosed
WO-1997031936-A2 NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1997-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12257230-B2 Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment IL17A, ACHE, IL1B NQO1 5/4885POR 1360/4885IDO1 1918/4885
US-20040266857-A1 Novel lapachone compounds and methods of use thereof XIAP, MKI67, PIN1 NQO1 4/4885POR 2496/4885IDO1 1021/4885
US-12370170-B2 Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment ACHE, NES, GSTO1 NQO1 11/4885POR 2987/4885IDO1 3195/4885
US-20250170252-A1 QUINONE PROTECTED FORMS AND CONJUGATES NQO1, SQOR, GSTP1 NQO1 1/4885POR 198/4885IDO1 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.